Spirair

Spirair is a private, commercial-stage medical device company targeting the large and underserved market for minimally invasive nasal airway correction. Its lead product, SeptAlign, is the first minimally invasive, bioabsorbable implant for mechanically correcting minor nasal septal deviation (NSD), offering a quick-recovery alternative to traditional septoplasty. The company is also developing TurbAlign for turbinate medialization, indicating a platform approach to nasal obstruction. With a leadership team combining Stanford Biodesign innovation, clinical ENT expertise, and commercial experience, Spirair is positioned to capture significant market share by empowering ENTs to treat a broader patient population.

Minimally invasive mechanical correction of nasal anatomy using bioabsorbable implants.

Spirair competes against traditional septoplasty and turbinate reduction surgery, which are the entrenched standards of care. It also faces competition from other minimally invasive office-based technologies for turbinate reduction (e.g., radiofrequency, microdebrider, cryotherapy), though its bioabsorbable implant approach for septal correction appears to be a first-in-class offering.